Results 261 to 270 of about 791,464 (334)

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Premixed Lidocaine With Fospropofol Disodium for Safety and Clinical Evaluation Regarding Paresthesia Upon Fospropofol Disodium Injection: A Preclinical Experimental Study and a Randomized Controlled Trial

MedComm, Volume 7, Issue 4, April 2026.
This study explored the effect of lidocaine premixing on fospropofol‐induced paresthesia. While the mixture of fospropofol (FP) and lidocaine (LD) proved chemically stable and safe in preclinical tests, clinical results from randomized controlled trial showed no reduction in paresthesia in FP+LD group compared with FP+NS group.
Bo Jiao, Xiaolin Xu, Ying Cui, Caiyi Yan, Liyun Deng, Dequan Zhong, Qing Yang, Jiqian Xu, Yi Liu, Xiaohui Sun, Mengqian Xu, Tao Liu, Hui Xu, Xuejiao Tang, Xiaoqin Luo, Peng Liang, Jin Liu, Chan Chen   +17 more
wiley   +1 more source

Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course

Journal of Cutaneous Pathology, Volume 53, Issue 4, Page 340-346, April 2026.
ABSTRACT Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T‐cell lymphoma (PCAECTCL) is a rare and aggressive malignancy, with limited documented cases in pediatric patients. This report presents a unique case of a 9‐year‐old female with PCAECTCL, characterized by widespread erythematous annular lesions that exhibited an indolent clinical ...
Carrie Meng, Auris Huen, David McCall, Phyu P. Aung, Priyadharsini Nagarajan, Valentina Nardi, Carlos A. Torres‐Cabala   +6 more
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, Volume 65, Issue 4, Page 706-723, April 2026.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

Graft and Patient Survival After Liver Transplantation for Primary Sclerosing Cholangitis: A French National Cohort Study

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background A significant proportion of patients presenting a primary sclerosing cholangitis (PSC) will require liver transplantation (LT). The present study aimed to investigate graft loss and patient death in a large cohort of patients. Methods We conducted a nationwide multicenter retrospective study including all adult patients transplanted
Florian Veyre, Claire Francoz, Domitille Erard, Eleonora DeMartin, Laure Elkrief, Camille Besch, Olivier Boillot, Filomena Conti, Sébastien Dharancy, Christophe Duvoux, Jean Gugenheim, Jean Hardwigsen, Marie‐Noëlle Hilleret, Vincent Leroy, Isabelle Ollivier‐Hourmand, Marilyne Gratien, Pauline Houssel‐Debry, Nassim Kamar, Olivier Roux, Jean‐Baptiste Hiriart, Marie Irles‐Depe, Sophie Pellegrin, François Durand, Georges‐Philippe Pageaux, Stéphanie Faure, Audrey Coilly, Sylvie Radenne, Faouzi Saliba, Didier Samuel, Claire Vanlemmens, Marianne Latournerie, Karim Boudjema, Ephrem Salamé, Olivier Chazouillères, Christophe Corpechot, Jérôme Dumortier   +35 more
wiley   +1 more source

Adult T‐cell leukemia/lymphoma in French Guiana (1990–2019): Epidemiology, clinical features, and HTLV‐1 genetic diversity in the two main ethnic populations

International Journal of Cancer, Volume 158, Issue 6, Page 1528-1540, 15 March 2026.
What's new? Adult T‐cell leukemia/lymphoma (ATL) is a rare and aggressive malignancy caused by human T‐cell leukemia virus type 1 (HTLV‐1). The authors comprehensively analyzed the epidemiological and clinical features of ATL over a 30‐year period in French Guiana, a region with high HTLV‐1 endemicity and a multiethnic population.
Jill‐Léa Ramassamy, Patricia Tortevoye, Balthazar Ntab, Gabriel Carles, Jean‐Pierre Droz, Pierre Couppié, Giovanni Begliomini, Jean‐Francois Carod, N'detodji‐Bill Wankpo, Karim Abdelmoumen, Philippe V. Afonso, Olivier Cassar, Antoine Talarmin, Olivier Hermine, Loïc Epelboin, Ambroise Marçais, Antoine Gessain   +16 more
wiley   +1 more source

The platelet transcriptome after stem cell transplantation

Clinical and Translational Discovery, Volume 6, Issue 2, April 2026.
Lin LI, Sidney W. Whiteheart, Reinhold Munker   +2 more
wiley   +1 more source

Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Myeloid sarcoma (MS) is a tumorous extramedullary proliferation of blast or blast equivalent cells (e.g., promonocytes or promyelocytes). The most frequent cutaneous presentation is often referred to as leukemia cutis (LC). These lesions, especially without the clinical context of a known bone marrow disease, pose a differential diagnostic ...
Alex Jenei, Béla Kajtár, Tamás László, Hazem A Juratli, Livia Vida, Ágota Szepesi, Réka Mózes, Botond Timár, Jörg Halter, Stefan Dirnhofer, Alexandar Tzankov   +10 more
wiley   +1 more source

Safety of Immune Checkpoint Inhibitors in Cancer Patients With Preexisting Autoimmune Vasculitis

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective Immune checkpoint inhibitors (ICIs) are effective cancer therapies but often cause serious immune‐related adverse events (irAEs). Patients with preexisting autoimmune diseases, including vasculitis, are excluded from trials. We aimed to evaluate the frequency, severity, and outcomes of vasculitis flares and irAEs in this population.
Juan Sevillano, Noha Abdel‐Wahab, Yixuan Zhou, Juan I. Ruiz, Maria E. Suarez‐Almazor   +4 more
wiley   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source